Clinical Trial Update: One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating long-term antibody persistence after booster dosing schedules of the Novartis Meningococcal B Recombinant Vaccine in infants and toddle…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Novartis Meningococcal B Recombinant Vaccine (recombinant meningococcal B vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease | Phase 3 | Status: COMPLETED | Results posted: 2015-04-10